Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

4

Revenue 2017

Herceptin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Herceptin was produced by Roche.

MSD launches EU’s first biosimilar Herceptin in UK

MSD launches EU’s first biosimilar Herceptin in UK Ontruzant was approved by the EMA last November for the full range of registered indications for Herceptin, including early breast cancer, metastatic breast cancer and metastatic gastric cancer. ... Clinical trials of the drug showed it to be comparable

The good, the bad and the ugly

The good, the bad and the ugly The main drivers of revenue for Roche are well-established, standard-of-care blockbuster oncology drugs including Rituxan, Herceptin and Avastin. ... Humira remains at the top, but Celgene’s Revlimid has jumped ahead of Roche’s Avastin, MabThera and

Roche faces biosimilar blitz in 2018

Roche faces biosimilar blitz in 2018 But Roche’s cancer antibody isn’t its only drug battling for market share - breast cancer blockbuster Herceptin (trastuzmab) also has a biosimilar rival in the form of Samsung Bioepis’ Ontruzant, ... which was approved last year for the full range

Novartis doubles down on biosimilars with Biocon alliance

Novartis doubles down on biosimilars with Biocon alliance drug Herceptin (trastuzumab) and Amgen's long-acting white cell booster Neulasta (pegfilgrastim) last August at the request of the EMA.

Roche buys cancer company Ignyta for $1.7bn

Roche buys cancer company Ignyta for $1.7bn It has been bolstering its oncology pipeline in particular as three of its top-selling drugs – Avastin, Herceptin and Rituxan – are starting to face biosimilar competition.

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics